Arde­lyx touts a PhI­II hy­per­phos­phatemia suc­cess for tena­panor, look­ing to calm fears over di­ar­rhea

Arde­lyx has been on a years-long roller coast­er ride with their drug tena­panor. But ear­ly this morn­ing the biotech $ARDX pulled the wraps off a Phase III study that they say met the pri­ma­ry end­point for treat­ing hy­per­phos­phatemia in pa­tients with end-stage re­nal dis­ease who were on dial­y­sis. And they add that they were able to do it with an ac­cept­able lev­el of prob­lems with di­ar­rhea — an is­sue that ear­li­er raised an alarm­ing warn­ing flag for in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.